Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Biosimilars | Current Treatment | Nephrology | US/EU | 2019

Login to access report north_east
Contact sales account_box

Erythropoiesis-stimulating agent (ESA) biosimilars entered the European market a decade ago, but only one ESA—Retacrit—has launched in the United States, and it did not launch until November 2018. Despite the availability of multiple ESA biosimilars for chronic kidney disease (CKD) for several years, their uptake in Europe has varied from country to country, as well as by drug and manufacturer. With new biosimilars expected to soon enter all markets, it is vital to understand why ESA biosimilar uptake varies in Europe and the likely impact of upcoming biosimilar launches in the United States and Europe. We surveyed nephrologists from France, Germany, and the United States to learn about their experience and familiarity with current biosimilars; the drivers of and barriers to these agents’ uptake; and their expectations for novel biosimilars.

Scope:

Markets covered: United States, France, and Germany.

Primary research: Online quantitative survey of 92 nephrologists.

Questions answered:

  • What is the current patient share of CKD biosimilars, and what expectations do nephrologists have for future patient shares?
  • How similar do nephrologists believe biosimilars are to their reference brands?
  • What factors do nephrologists identify as being the key drivers of and barriers to biosimilar uptake?
  • What percentage of biosimilar-treated patients were initiated on a biosimilar, and what percentage were switched from a reference brand?
  • What cost reduction is required for a biosimilar to achieve more than a 50% patient share?

Key markets covered:

  • France
  • Germany
  • United States

Key companies mentioned:

  • Amgen
  • Janssen
  • Johnson & Johnson
  • Medice Arzneimittel Putter
  • Pfizer
  • Roche
  • Sandoz (Novartis)
  • Stada Arzneimittel
  • Vifor Pharma

Key drugs mentioned:

  • Abseamed
  • Aranesp
  • Binocrit
  • Epoetin Alfa Hexal
  • Epogen
  • Eprex/Erypro
  • Mircera
  • NeoRecormon
  • Procrit
  • Retacrit
  • Silapo
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east